CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
David A. Flockhart(Indiana University – Purdue University Indianapolis), Todd C. Skaar(Indiana University School of Medicine), L. Ullmer(University of Michigan), Suzanne Lemler, Anne Nguyen(Indiana University School of Medicine), Jill A. Hayden(Northwestern University), James M. Rae(University of Michigan), Anna Maria Storniolo(Indiana University Health), Richard M. Weinshilboum(Mayo Clinic), Vered Stearns(Johns Hopkins University), Rebecca Blanchard(Fox Chase Cancer Center), Daniel F. Hayes(University of Michigan–Ann Arbor), K.-H. Lee(Indiana University Bloomington), Brent B. Ward(University of Michigan), Zeruesenay Desta(Indiana University School of Medicine), Lü Li(McGill University), A. Araba(Mayo Clinic), H Ho(Indiana University Bloomington)
Cited by 947
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k